Real-time metagenomics-based diagnosis of community-acquired meningitis: A prospective series, southern France.
Antibiotic resistance
Community-acquired meningitis
Genotyping
Point-of-care (POC) laboratory diagnosis
Real-time metagenomics
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
10
01
2022
revised:
16
08
2022
accepted:
16
08
2022
pubmed:
11
9
2022
medline:
19
10
2022
entrez:
10
9
2022
Statut:
ppublish
Résumé
Point-Of-Care (POC) diagnosis of life-threatening community-acquired meningitis currently relies on multiplexed RT-PCR assays, that lack genotyping and antibiotic susceptibility profiling. We assessed the usefulness of real-time metagenomics (RTM) directly applied to the cerebrospinal fluid (CSF) for the identification, typing and susceptibility profiling of pathogens responsible for community-acquired meningitis. A series of 52 CSF samples from patients suspected of having community-acquired meningitis, were investigated at POC by direct RTM in parallel to routine real-time multiplex PCR (RT-PCR) and bacterial culture, for the detection of pathogens. RTM-generated sequences were blasted in real-time against an in-house database incorporating the panel of 12 most prevalent pathogens and against NCBI using EPI2ME online software, for pathogen identification. In-silico antibiogram and genotype prediction were determined using the ResFinder bio-tool and MLST online software. Over eight months, routine multiplex RT-PCR yielded 49/52 positive CSFs, including 21 Streptococcus pneumoniae, nine Neisseria meningitidis, eight Haemophilus influenzae, three Streptococcus agalactiae, three Herpesvirus-1, two Listeria monocytogenes, and one each of Escherichia coli, Staphylococcus aureus and Varicella-Zoster Virus. Parallel RTM agreed with the results of 47/52 CSFs and revealed two discordant multiplex RT-PCR false positives, one H. influenzae and one S. pneumoniae. Both multiplex RT-PCR and RTM agreed on the negativity of three CSFs. While multiplex RT-PCR routinely took 90 min, RTM took 120 min, although the pipeline analysis detected the pathogen genome after 20 min of sequencing in 33 CSF samples; and after two hours in 14 additional CSFs; yielding > 50% genome coverage in 19 CSFs. RTM identified 14 pathogen genotypes, including a majority of H. influenzae b, N. meningitidis B and S. pneumoniae 11A and 3A. In all 16 susceptible cultured bacteria, the in-silico antibiogram agreed with the in-vitro antibiogram in 10 cases, available within 48 h in routine bacteriology. In addition to pathogen detection, RTM applied to CSF samples offered supplementary information on bacterial profiling and genotyping. These data provide the proof-of-concept that RTM could be implemented in a POC laboratory for one-shot diagnostic and genomic surveillance of pathogens responsible for life-threatening meningitis. This work was supported by the French Government under the Investments in the Future programme managed by the National Agency for Research reference: Méditerranée Infection 10-IAHU-03.
Sections du résumé
BACKGROUND
BACKGROUND
Point-Of-Care (POC) diagnosis of life-threatening community-acquired meningitis currently relies on multiplexed RT-PCR assays, that lack genotyping and antibiotic susceptibility profiling. We assessed the usefulness of real-time metagenomics (RTM) directly applied to the cerebrospinal fluid (CSF) for the identification, typing and susceptibility profiling of pathogens responsible for community-acquired meningitis.
METHODS
METHODS
A series of 52 CSF samples from patients suspected of having community-acquired meningitis, were investigated at POC by direct RTM in parallel to routine real-time multiplex PCR (RT-PCR) and bacterial culture, for the detection of pathogens. RTM-generated sequences were blasted in real-time against an in-house database incorporating the panel of 12 most prevalent pathogens and against NCBI using EPI2ME online software, for pathogen identification. In-silico antibiogram and genotype prediction were determined using the ResFinder bio-tool and MLST online software.
FINDINGS
RESULTS
Over eight months, routine multiplex RT-PCR yielded 49/52 positive CSFs, including 21 Streptococcus pneumoniae, nine Neisseria meningitidis, eight Haemophilus influenzae, three Streptococcus agalactiae, three Herpesvirus-1, two Listeria monocytogenes, and one each of Escherichia coli, Staphylococcus aureus and Varicella-Zoster Virus. Parallel RTM agreed with the results of 47/52 CSFs and revealed two discordant multiplex RT-PCR false positives, one H. influenzae and one S. pneumoniae. Both multiplex RT-PCR and RTM agreed on the negativity of three CSFs. While multiplex RT-PCR routinely took 90 min, RTM took 120 min, although the pipeline analysis detected the pathogen genome after 20 min of sequencing in 33 CSF samples; and after two hours in 14 additional CSFs; yielding > 50% genome coverage in 19 CSFs. RTM identified 14 pathogen genotypes, including a majority of H. influenzae b, N. meningitidis B and S. pneumoniae 11A and 3A. In all 16 susceptible cultured bacteria, the in-silico antibiogram agreed with the in-vitro antibiogram in 10 cases, available within 48 h in routine bacteriology.
INTERPRETATION
CONCLUSIONS
In addition to pathogen detection, RTM applied to CSF samples offered supplementary information on bacterial profiling and genotyping. These data provide the proof-of-concept that RTM could be implemented in a POC laboratory for one-shot diagnostic and genomic surveillance of pathogens responsible for life-threatening meningitis.
FUNDING
BACKGROUND
This work was supported by the French Government under the Investments in the Future programme managed by the National Agency for Research reference: Méditerranée Infection 10-IAHU-03.
Identifiants
pubmed: 36087524
pii: S2352-3964(22)00429-7
doi: 10.1016/j.ebiom.2022.104247
pmc: PMC9463524
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104247Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no conflicts of interest. In particular, the authors did not receive any contribution from any of the suppliers mentioned in this report.
Références
BMC Infect Dis. 2015 Oct 14;15:419
pubmed: 26468008
Viruses. 2021 Nov 16;13(11):
pubmed: 34835092
Nat Med. 2021 Jan;27(1):115-124
pubmed: 33169017
N Engl J Med. 2019 Jun 13;380(24):2327-2340
pubmed: 31189036
Nat Microbiol. 2020 Mar;5(3):443-454
pubmed: 31932713
PLoS One. 2018 Jun 11;13(6):e0198772
pubmed: 29889859
PLoS One. 2019 Oct 24;14(10):e0223887
pubmed: 31647847
Antibiotics (Basel). 2020 May 26;9(6):
pubmed: 32466378
Eur J Clin Microbiol Infect Dis. 2020 Aug;39(8):1573-1580
pubmed: 32358740
J Clin Microbiol. 2016 Dec 28;55(1):336-338
pubmed: 27795349
Mil Med. 2018 Jan 1;183(1-2):e24-e27
pubmed: 29401338
Clin Microbiol Infect. 2020 Mar;26(3):281-290
pubmed: 31760115
J Mol Microbiol Biotechnol. 2001 Apr;3(2):219-24
pubmed: 11321577
Front Cell Infect Microbiol. 2018 Oct 23;8:375
pubmed: 30406048
Lancet Microbe. 2022 Jan;3(1):e6
pubmed: 35544115
Pathog Glob Health. 2013 Jan;107(1):15-20
pubmed: 23432859
Pathogens. 2021 Apr 12;10(4):
pubmed: 33921275
Nat Rev Dis Primers. 2016 Nov 03;2:16074
pubmed: 27808261
Nat Microbiol. 2020 Mar;5(3):430-442
pubmed: 31844297
Euro Surveill. 2018 Nov;23(44):
pubmed: 30401013
J Mol Diagn. 2020 Mar;22(3):405-418
pubmed: 32146977
Med J Aust. 2018 Nov 19;209(10):449-454
pubmed: 30309300
J Pharm Pract. 2019 Feb;32(1):36-40
pubmed: 29092659
J Clin Microbiol. 2016 Sep;54(9):2251-61
pubmed: 27335149
J Infect. 2021 Dec;83(6):709-737
pubmed: 34627841
Clin Microbiol Infect. 2020 Sep;26(9):1192-1200
pubmed: 31927117
Clin Microbiol Rev. 2016 Jul;29(3):429-47
pubmed: 27029593